Namibia - English - Namibia Medicines Regulatory Council

sandoz s a (pty) ltd - beclomethasone dipropionate - nasal spray - each metered spray contains 50?g beclomethasone dipropionate

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 40 ug

United States - English - NLM (National Library of Medicine)

stat rx usa llc - beclomethasone dipropionate monohydrate (unii: 4h7l9ai22i) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate monohydrate 42 ug - beconase aq nasal spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. however, symptomatic relief may not occur in some patients for as long as 2 weeks. beconase aq nasal spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. beconase aq nasal spray should not be used in the presence of untreated localized infection involving the nasal mucosa. beconase aq nasal spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. hypersensitivity to an

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - beclomethasone dipropionate monohydrate (unii: 4h7l9ai22i) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 42 ug - beconase aq nasal spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. however, symptomatic relief may not occur in some patients for as long as 2 weeks. beconase aq nasal spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. beconase aq nasal spray should not be used in the presence of untreated localized infection involving the nasal mucosa. beconase aq nasal spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. hypersensitivity to any of the in

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - beclomethasone dipropionate anhydrous usp -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 80 ug - qvar® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. important limitations of use: - qvar is not indicated for the relief of acute bronchospasm. 4.1 status asthmaticus qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. 4.2 hypersensitivity qvar is contraindicated in patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in qvar [see warnings and precautions (5.6)]. risk summary there are no adequate and well-controlled studies with qvar or beclomethasone dipropionate in pregnant women. there are clinical considerations with the use of inhaled corticosteroids (ics), including beclomethasone dipropionate, in pregnant women [see clinical considerations] . also, no published studies, including studies of large birth registries, have to date related the use of ics to any increases in congenital malformations or other

Canada - English - Health Canada

kenral inc. - beclomethasone dipropionate - metered-dose aerosol - 50mcg - beclomethasone dipropionate 50mcg - anti-inflammatory agents

Canada - English - Health Canada

pharmaco canada inc. - beclomethasone dipropionate - metered-dose aerosol - 50mcg - beclomethasone dipropionate 50mcg - anti-inflammatory agents

Canada - English - Health Canada

prempharm inc - beclomethasone dipropionate - metered-dose aerosol - 50mcg - beclomethasone dipropionate 50mcg - corticosteroids

Kenya - English - Pharmacy and Poisons Board

cachet pharmaceuticals pvt. ltd. 415, shah nahar, worli, mumbai-400018. - beclomethasone dipropionate usp, neomycin… - cream - beclomethasone dipropionate… - beclometasone and antibiotics